If you have been reading about T-alpha-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Hygroscopic; let the vial equilibrate before opening |
| Solubility | Freely soluble in water and aqueous buffers | Working solutions are often prepared between 0.1 and 1 mg per mL |
| Typical storage temperature | At or below 20 degrees below zero Celsius | Desiccant and sealed vials reduce moisture uptake |
| Routine purity assay | Reversed-phase HPLC with ultraviolet detection | Result reported as percentage of total peak area |
| Identity check | Mass spectrometry with amino acid analysis | Observed mass is compared with the calculated value |
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
==== On Natural Amino Acids ==== Trp arylation Multiple methods have been reported to achieve tryptophan C–H arylation, where diverse electrophiles such as aryl halides and aryl boronic acids (an example shown below) have been used to transfer the aryl groups. However, current tryptophan C–H arylation reaction conditions remain relatively harsh, requiring organic solvents, low pH and/or high temperatures.
== Toponym == The name of the town was attested in 1489, even before it was founded by François I in the form le Hable de Grace then Ville de Grace in 1516, two years before its official founding. The learned and transient name of Franciscopolis in tribute to the same king, is encountered in some documents then that of Havre Marat, referring to Jean-Paul Marat during the French Revolution but was not imposed. However it explains why the complementary determinant -de-Grace was not restored. This qualifier undoubtedly referred to the Chapel of Notre Dame located at the site of the cathedral of the same name. The chapel faced the Chapel Notre Dame de Grace of Honfleur across the estuary. The common noun havre meaning 'port' was out of use at the end of the 18th or beginning of the 19th centuries but is still preserved in the phrase havre de paix meaning 'safe haven'. It is generally considered a loan from Middle Dutch from the 12th century. A Germanic origin can explain the "aspiration" of the initial h. Havre de Grace, Maryland, in the United States retains the de Grace from colonial times. New research however focuses on the fact that the term was attested very early (12th century) and in Norman texts in the forms Hable, hafne, havene, havne, and haule makes a Dutch origin unlikely.
The two substrates of this enzyme are L-xylose and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are L-xylono-1,4-lactone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-xylose:NADP+ 1-oxidoreductase. Other names in common use include L-xylose dehydrogenase, and NADPH-xylose reductase.
=== Enzyme activity === Enzyme activity is a measure of the quantity of active enzyme present and is thus dependent on various physical conditions, which should be specified. It is calculated using the following formula:
This process continues until the entire chain is cleaved into acetyl CoA units. The final cycle produces two separate acetyl CoAs, instead of one acyl CoA and one acetyl CoA. For every cycle, the Acyl CoA unit is shortened by two carbon atoms. Concomitantly, one molecule of FADH2, NADH and acetyl CoA are formed.
Sources: en.wikipedia.org
== Pace-of-play initiatives == As a part of pace-of-play initiatives implemented in 2015, 20-second pitch clocks entered use at Double-A stadiums in 2015. In 2018, the time was shortened to 15 seconds when no runners are on base. Other significant changes implemented in 2018 included beginning extra innings with a runner on second base and limiting teams to eight mound visits during a nine-inning game. In 2019, the number of mound visits was reduced to seven, and pitchers were required to face a minimum of three consecutive batters, unless the side is retired or the pitcher is injured and unable to continue.
==== 1.G Viral fusion pores ==== 1.G.1 The Viral Pore-forming Membrane Fusion Protein-1 (VMFP1) Family 1.G.2 The Viral Pore-forming Membrane Fusion Protein-2 (VMFP2) Family 1.G.3 The Viral Pore-forming Membrane Fusion Protein-3 (VMFP3) Family 1.G.4 The Viral Pore-forming Membrane Fusion Protein-4 (VMFP4) Family 1.G.5 The Viral Pore-forming Membrane Fusion Protein-5 (VMFP5) Family 1.G.6 The Hepadnaviral S Fusion Protein (HBV-S Protein) Family 1.G.7 The Reovirus FAST Fusion Protein (R-FAST) Family 1.G.8 The Arenavirus Fusion Protein (AV-FP) Family 1.G.9 The Syncytin (Syncytin) Family 1.G.10 The Herpes Simplex Virus Membrane Fusion Complex (HSV-MFC) Family 1.G.11 Poxvirus Cell Entry Protein Complex (PEP-C) Family 1.G.12 The Avian Leukosis Virus gp95 Fusion Protein (ALV-gp95) Family 1.G.13 The Orthoreovirus Fusion-associated Small Transmembrane (FAST) Family 1.G.14 The Influenza Virus Hemagglutinin/Fusion Pore-forming Protein (Influenza-H/FPP) Family 1.G.15 The Autographa californica Nuclear Polyhedrosis Virus Major Envelope Glycoprotein GP64 (GP64) Family 1.G.16 The Human Immunodeficiency Virus Type 1 (HIV-1) Fusion Peptide (HIV-FP) Family 1.G.17 The Bovine Leukemia Virus Envelop Glycoprotein (BLV-Env) Family 1.G.18 The SARS-CoV Fusion Peptide in the Spike Glycoprotein Precursor (SARS-FP) Family 1.G.19 The Rotavirus Pore-forming Membrane Fusion Complex (Rotavirus MFC) Family 1.G.20 The Hantavirus Gc Envelope Fusion Glycoprotein (Gc-EFG) Family 1.G.21 The Epstein Barr Virus (Human Herpes Virus 4) Gp42 (Gp42) Family 1.G.22 The Cytomegalovirus (Human Herpesvirus 5) Glycoprotein gO (gO) Family
=== Personal motto === "With united forces" (as the Emperor of Austria) – German: "Mit vereinten Kräften" – Latin: "Viribus Unitis" "My trust in [the ancient] virtue" (as the Apostolic King of Hungary) – Hungarian: "Bizalmam az Ősi Erényben" – Latin: "Virtutis Confido"
2 Fe2O3 + 3 C → 4 Fe + 3 CO2 The flux removes silicaceous minerals in the ore, which would otherwise clog the furnace: The heat of the furnace decomposes the carbonates to calcium oxide, which reacts with any excess silica to form a slag composed of calcium silicate CaSiO3 or other products. At the furnace's temperature, the metal and the slag are both molten. They collect at the bottom as two immiscible liquid layers (with the slag on top), that are then easily separated. The slag can be used as a material in road construction or to improve mineral-poor soils for agriculture. Steelmaking thus remains one of the largest industrial contributors of CO2 emissions in the world.
Gamma-Dynacare Medical Laboratories is a Canadian medical laboratory services company based in Brampton, Ontario, Canada. Dynacare operates laboratories in Brampton, Bowmanville, London, Ottawa, Thunder Bay, Pointe-Claire, Laval, and Winnipeg. In addition to the main laboratories Dynacare operates patient services centers throughout Ontario, Quebec, Manitoba, Saskatchewan, Alberta and British Columbia. Dynacare is an operational partnership founded in 1997 as Gamma-Dynacare between: Dynacare Laboratories; Gamma North Peel Partnership Inc.; and Bio-Science Laboratory (Ontario) Limited. In 2002 Dynacare Laboratories (one of the Dynacare partners) was acquired by LabCorp for $480-million (U.S.) while also assuming Dynacare debt worth $205-million. In 2015, it rebranded itself back to Dynacare. In 2011 Dynacare acquired the medical laboratory division of Warnex Inc. (TSX:WNX) for $7.5 Million. In 2023 Dynacare acquired the medical laboratories in British Columbia known as Valley Medical Laboratories. This increased the Dynacare presence in British Columbia by adding about 12 locations in Kelowna and throughout the Okanagan Valley.
Sources: en.wikipedia.org
Jonathan Vilma, a Saints player who had a major role in the scheme and reportedly offered a $10,000 bounty on Brett Favre, was suspended for the entire season and three other players were suspended for parts of the season. However, in September 2012, an arbitrator overturned the suspensions of the players involved in the affair. Williams' suspension ultimately lasted one year. Deflategate (2015) – during the AFC Championship Game, 11 of the 12 footballs under the Patriots' control during the first half were found to be inflated below the level mandated by the rulebook. The case was then closed because of the referees' failure to check the balls prior to the game. Tom Brady was suspended by the NFL for the first 4 games of the 2016 season.
=== Pharmacogenetics === The predominant enzyme responsible for metabolism of tacrolimus is CYP3A5. Genetic variations within CYP3A5 that result in changes to the activity of the CYP3A5 protein can affect concentrations of tacrolimus within the body. In particular, individuals who are homozygous for the G allele at the single nucleotide polymorphism (SNP) rs776746 (also known as CYP3A5 *3/*3) have a non-functional CYP3A5 protein. The frequency of the G allele varies worldwide, from 4% in some African populations to 80–90% in Caucasian populations. Across a large number of studies, individuals homozygous for the G allele have been shown to have higher concentrations of tacrolimus and require lower doses of the drug, as compared to individuals who are not homozygous for the G allele. Achieving target concentrations of tacrolimus is important – if levels are too low, then there is a risk of transplant rejection, if levels are too high, there is a risk of drug toxicities. There is evidence to suggest that dosing patients based on rs776746 genotype can result in faster and more frequent achievement of target tacrolimus levels. However, there is a lack of consistent evidence as to whether dosing based on rs776746 genotype results in improved clinical outcomes (such as a decreased risk for transplant rejection or drug toxicities), likely because patients taking tacrolimus are subject to therapeutic drug monitoring. Studies have shown that genetic polymorphisms of genes other than CYP3A5, such as NR1I2 (encoding PXR), also significantly influence the pharmacokinetics of tacrolimus.
=== Singles series and Full Cold Moon (2012–present) === In September 2012, Eisold announced Cold Cave would be touring the US later in the year, he would be recording a new album, and that the new live lineup included: Hunter Burgan (AFI), London May (Samhain), Jessie Nelson, and Cody Votolato (The Blood Brothers). This lineup was exclusive to this two-and-a-half-week tour and Eisold said performing with a full band was something that failed to materialize during Cherish the Light Years tours. While continuing to work on a follow-up to Cherish the Light Years and not under contract with a label, Eisold began independently releasing a series of stand-alone singles. Eisold wrote and recorded these new songs by himself similar to how songs on Cremations and Love Comes Close were crafted. He said they were created "by myself, at a desk in my apartment. It was freeing and exciting in a way because I didn't owe anyone an album. I got to just make them to make them. The songs were minimal, honest, electronic and without help." The first single in the series was "A Little Death to Laugh." The single was released in October 2012 through Heartworm and a music video for the song was released in March 2013. In 2013, Eisold released "Oceans with No End" (through Jacob Bannon's Deathwish Inc.), "God Made the World" and "Black Boots", for which Slava Tsukerman, known for his 1982 film Liquid Sky, directed a music video. In October 2013, Cold Cave released a digital-only, fifth stand-alone single titled "Nausea, The Earth and Me."
Prior to any physical examination, the diagnosis of keratoconus frequently begins with an ophthalmologist's or optometrist's assessment of the person's medical history, particularly the chief complaint and other visual symptoms, the presence of any history of ocular disease or injury that might affect vision, and the presence of any family history of ocular disease. An eye chart, such as a standard Snellen chart of progressively smaller letters, is then used to determine the person's visual acuity. The eye examination may proceed to measurement of the localized curvature of the cornea with a manual keratometer, with detection of irregular astigmatism suggesting a possibility of keratoconus. Severe cases can exceed the instrument's measuring ability. A further indication can be provided by retinoscopy, in which a light beam is focused on the person's retina and the reflection, or reflex, observed as the examiner tilts the light source back and forth. Keratoconus is amongst the ophthalmic conditions that exhibit a scissor reflex action of two bands moving toward and away from each other like the blades of a pair of scissors. If keratoconus is suspected, the ophthalmologist or optometrist will search for other characteristic findings of the disease by means of slit lamp examination of the cornea. An advanced case is usually readily apparent to the examiner, and can provide for an unambiguous diagnosis prior to more specialized testing.
===== MeSH D08.811.913.817 – sulfur group transferases (EC 2.8) ===== MeSH D08.811.913.817.200 – coenzyme a-transferases MeSH D08.811.913.817.400 – sulfotransferases MeSH D08.811.913.817.400.300 – aryl sulfotransferase MeSH D08.811.913.817.500 – sulfurtransferases MeSH D08.811.913.817.500.500 – thiosulfate sulfurtransferase
Sources: en.wikipedia.org
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.
Research material is commonly offered at 95 percent purity or above by chromatographic area, with some suppliers listing 98 percent. Higher grades usually carry a higher price and are chosen when the assay is sensitive to trace impurities.
Mass spectrometry is the standard check, often paired with amino acid analysis or peptide mapping. A chromatographic retention time alone is generally considered insufficient for structural confirmation.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.